Acrivon Therapeutics, Inc. Common Stock (ACRV) vs ProMIS Neurosciences, Inc. (PMN)
A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and ProMIS Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.88HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
PMN
ProMIS Neurosciences, Inc.
$9.37HealthcareDelayed quote: Oct 6, 2026, 1:53 PM EDT
Total return — ACRV vs PMN
growth of $100 · dividends reinvested · last 4yACRV -88.1% (-41.3%/yr)PMN -93.5% (-49.6%/yr)ACRV compounded faster over this window
ACRV PMN
ACRV vs PMN: by the numbers
- •PMN is the larger company ($84M vs $80M market cap).
Metrics side by side
Valuation
| Metric | ACRV | PMN |
|---|---|---|
| P/B ratio | 0.93 | 1.70 |
Profitability
| Metric | ACRV | PMN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -85.65% | -85.48% |
| ROIC | -88.28% | -87.79% |
Growth (annualized)
| Metric | ACRV | PMN |
|---|---|---|
| Total return CAGR (5Y) | N/A | -47.05% |
Go deeper
Dig into the metrics
Acrivon Therapeutics, Inc. Common Stock ROEProMIS Neurosciences ROEAcrivon Therapeutics, Inc. Common Stock operating marginProMIS Neurosciences operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthProMIS Neurosciences revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowProMIS Neurosciences free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.